# Cloud P. Paweletz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/cloud-p-paweletz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,827 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 73 |
| i10-index | 145 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5056573353 |
| ORCID iD | 0000-0002-2287-5663 |
| Works | 760 |

## Researcher papers

Showing 12 of 17.

- [Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma](https://scholariq.org/papers/defining-t-cell-states-associated-with-response-to-checkpoint-immunotherapy-in/)
- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front](https://scholariq.org/papers/reverse-phase-protein-microarrays-which-capture-disease-progression-show/)
- [Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib/)
- [CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation](https://scholariq.org/papers/cdk4-6-inhibition-augments-antitumor-immunity-by-enhancing-t-cell-activation/)
- [Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA](https://scholariq.org/papers/noninvasive-detection-of-response-and-resistance-in-i-egfr-i-mutant-lung-cancer/)
- [Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib](https://scholariq.org/papers/assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-i/)
- [<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids](https://scholariq.org/papers/i-ex-vivo-i-profiling-of-pd-1-blockade-using-organotypic-tumor-spheroids/)
- [Prospective Validation of Rapid Plasma Genotyping for the Detection of<i>EGFR</i>and<i>KRAS</i>Mutations in Advanced Lung Cancer](https://scholariq.org/papers/prospective-validation-of-rapid-plasma-genotyping-for-the-detection-of-i-egfr-i/)
- [Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer](https://scholariq.org/papers/suppression-of-sting-associated-with-lkb1-loss-in-kras-driven-lung-cancer/)
- [Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway](https://scholariq.org/papers/treatment-induced-tumor-dormancy-through-yap-mediated-transcriptional/)
- [False-Positive Plasma Genotyping Due to Clonal Hematopoiesis](https://scholariq.org/papers/false-positive-plasma-genotyping-due-to-clonal-hematopoiesis/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [interferon and immune responses](https://scholariq.org/topics/interferon-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.